{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:17:41Z","timestamp":1791357461118,"version":"4.3.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Naldemedine, a novel peripherally-acting mu-opioid receptor antagonist, has improved opioid-induced constipation in randomized controlled trials. The most frequent adverse event of naldemedine is diarrhea, which can cause abdominal pain and often leads to treatment discontinuation. We aimed to identify risk factors and appropriate management strategies for key adverse events including diarrhea associated with naldemedine, since those have not been extensively studied.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We conducted a multi-center retrospective cohort study. Eligible patients had cancer, had undergone palliative care at participating centers, had been prescribed regular opioids, and had taken at least one dose of naldemedine between June 2017 and March 2018. The primary endpoint was the incidence of diarrhea according to baseline characteristics. Secondary endpoints included the duration of naldemedine administration, daily defecation counts before and after starting naldemedine, duration and severity of diarrhea as an adverse event of naldemedine, other adverse events, and the incidence of constipation within 7\u2009days after recovery from diarrhea. We defined patients who started naldemedine within three days of starting a regularly prescribed opioid as the early group, and the remainder as the late group.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Among 103 patients who received naldemedine, 98 fulfilled the eligibility criteria. The median age was 68\u2009years and 48% of the patients were female. Median performance status was 3, and the median oral intake was 50%. The median duration of naldemedine administration and overall survival were 25 and 64\u2009days, respectively. The incidence of diarrhea in the early group (<jats:italic>n<\/jats:italic>\u2009=\u200926) was significantly lower than in the late group (<jats:italic>n<\/jats:italic>\u2009=\u200972) (3.9% vs. 22.2%, <jats:italic>p<\/jats:italic>\u2009=\u20090.02). Daily defecation counts increased after late (median 0.43 to 0.88, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), but remained stable after early naldemedine administration (median 1.00 to 1.00, <jats:italic>p<\/jats:italic>\u2009=\u20090.34). Constipation after the diarrhea was resolved was common (53%), especially among patients who stopped naldemedine (78%). The diarrhea was improved within three days in 92% of patients who stopped other laxatives.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The early administration of naldemedine is beneficial because it reduces adverse events including diarrhea. Diarrhea caused by naldemedine can be effectively managed by stopping other laxatives while continuing naldemedine.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12876-020-1173-z","type":"journal-article","created":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T17:03:05Z","timestamp":1580490185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0305-1597","authenticated-orcid":false,"given":"Yusuke","family":"Takagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gakuji","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoriko","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Ikezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Aruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,31]]},"reference":[{"key":"1173_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","volume":"10","author":"TJ Bell","year":"2009","unstructured":"Bell TJ, Panchal SJ, Miaskowski C, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med. 2009;10:35\u201342.","journal-title":"Pain Med"},{"key":"1173_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/AJP.0b013e318237d626","volume":"28","author":"M Ishihara","year":"2012","unstructured":"Ishihara M, Ikesue H, Matsunaga H, et al. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain. 2012;28:373\u201381.","journal-title":"Clin J Pain"},{"key":"1173_CR3","first-page":"CD011056","volume":"5","author":"PJ Wiffen","year":"2014","unstructured":"Wiffen PJ, Derry S, Moore RA. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database Syst Rev. 2014;5:CD011056.","journal-title":"Cochrane Database Syst Rev"},{"key":"1173_CR4","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1177\/0269216311404273","volume":"25","author":"EA Laugsand","year":"2011","unstructured":"Laugsand EA, Kaasa S, Klepstad P. Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations. Palliat Med. 2011;25:442\u201353.","journal-title":"Palliat Med"},{"key":"1173_CR5","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1111\/pme.12724","volume":"16","author":"KS Coyne","year":"2015","unstructured":"Coyne KS, Margolis MK, Yeomans K, et al. Opioid-induced constipation among patients with chronic noncancer pain in the United States, Canada, Germany, and the United Kingdom: laxative use, response, and symptom burden over time. Pain Med. 2015;16:1551\u201365.","journal-title":"Pain Med"},{"key":"1173_CR6","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s00134-015-4050-4","volume":"42","author":"R Smonig","year":"2016","unstructured":"Smonig R, Wallenhorst T, Bouju P, et al. Constipation is independently associated with delirium in critically ill ventilated patients. Intensive Care Med. 2016;42:126\u20137.","journal-title":"Intensive Care Med"},{"key":"1173_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.5055\/jom.2015.0282","volume":"11","author":"S Gupta","year":"2015","unstructured":"Gupta S, Patel H, Scopel J, et al. Impact of constipation on opioid therapy management among long-term opioid users, based on a patient survey. J Opioid Manag. 2015;11:325\u201338.","journal-title":"J Opioid Manag"},{"key":"1173_CR8","first-page":"345","volume":"7","author":"JL Poulsen","year":"2014","unstructured":"Poulsen JL, Brock C, Olesen AE, et al. Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. Clin Exp Gastroenterol. 2014;7:345\u201358.","journal-title":"Clin Exp Gastroenterol"},{"key":"1173_CR9","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/MEG.0000000000000574","volume":"28","author":"M Nilsson","year":"2016","unstructured":"Nilsson M, Poulsen JL, Brock C, et al. Opioid-induced bowel dysfunction in healthy volunteers assessed with questionnaires and MRI. Eur J Gastroenterol Hepatol. 2016;28:514\u201324.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1173_CR10","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1001\/jama.283.3.367","volume":"283","author":"CS Yuan","year":"2000","unstructured":"Yuan CS, Foss JF, O'Connor M, et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA. 2000;283:367\u201372.","journal-title":"JAMA"},{"key":"1173_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.pain.2007.11.008","volume":"137","author":"L Webster","year":"2008","unstructured":"Webster L, Jansen JP, Peppin J, et al. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. Pain. 2008;137:428\u201340.","journal-title":"Pain"},{"key":"1173_CR12","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1310246","volume":"370","author":"WD Chey","year":"2014","unstructured":"Chey WD, Webster L, Sostek M, et al. Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med. 2014;370:2387\u201396.","journal-title":"N Engl J Med"},{"key":"1173_CR13","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1200\/JCO.2017.73.0853","volume":"35","author":"N Katakami","year":"2017","unstructured":"Katakami N, Harada T, Murata T, et al. Randomized phase III and extension studies of Naldemedine in patients with opioid-induced constipation and Cancer. J Clin Oncol. 2017;35:3859\u201366.","journal-title":"J Clin Oncol"},{"key":"1173_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/S0885-3924(01)00369-4","volume":"23","author":"M Liu","year":"2002","unstructured":"Liu M, Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manag. 2002;23:48\u201353.","journal-title":"J Pain Symptom Manag"},{"issue":"suppl","key":"1173_CR15","doi-asserted-by":"publisher","first-page":"S537","DOI":"10.1016\/S0016-5085(16)31849-2","volume":"150","author":"K Fukumura","year":"2016","unstructured":"Fukumura K, Yokota T, Baba Y, et al. Phase 1, randomized, double-blind, placebo-controlled studies of the safety, tolerability and pharmacokinetics of naldemedine in healthy volunteers. Gastroenterology. 2016;150(suppl):S537\u20138.","journal-title":"Gastroenterology"},{"key":"1173_CR16","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1200\/JCO.2016.70.8453","volume":"35","author":"N Katakami","year":"2017","unstructured":"Katakami N, Oda K, Tauchi K, et al. Phase IIb, randomized, double-blind, placebo-controlled study of Naldemedine for the treatment of opioid-induced constipation in patients with Cancer. J Clin Oncol. 2017;35:1921\u20138.","journal-title":"J Clin Oncol"},{"key":"1173_CR17","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1093\/pm\/pnw325","volume":"18","author":"LR Webster","year":"2017","unstructured":"Webster LR, Yamada T, Arjona Ferreira JC. A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of Naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Med. 2017;18:2350\u201360.","journal-title":"Pain Med"},{"key":"1173_CR18","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.jpainsymman.2010.02.019","volume":"40","author":"F Hjalte","year":"2010","unstructured":"Hjalte F, Berggren AC, Bergendahl H, et al. The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manag. 2010;40:696\u2013703.","journal-title":"J Pain Symptom Manag"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-1173-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-020-1173-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-1173-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T00:12:09Z","timestamp":1611965529000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-020-1173-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,31]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1173"],"URL":"https:\/\/doi.org\/10.1186\/s12876-020-1173-z","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,31]]},"assertion":[{"value":"30 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol included a waiver of the need for written informed consent, which was approved by the institutional review boards at all participating centers (Teikyo University Review Committee: 17\u2013122; Toda-chuo General Hospital Review Committee: 0355).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author YT and EA received research funding and honoraria from Shionogi. Author GO received research funding from Shionogi. Authors YK, EI and CK have no financial relationships to report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}